Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49


Phase 1 dose-escalating study to evaluate the safety, pharmacokinetics, and pharmacodynamics of a recombinant factor Xa variant (FXaI16L ).

Parsons-Rich D, Hua F, Li G, Kantaridis C, Pittman DD, Arkin S.

J Thromb Haemost. 2017 May;15(5):931-937. doi: 10.1111/jth.13673. Epub 2017 Apr 25.


Stent-Retriever Thrombectomy for Stroke.

Saver JL, Goyal M, Diener HC; SWIFT PRIME Investigators..

N Engl J Med. 2015 Sep 10;373(11):1077. doi: 10.1056/NEJMc1508744. No abstract available.


Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, Jansen O, Jovin TG, Mattle HP, Nogueira RG, Siddiqui AH, Yavagal DR, Baxter BW, Devlin TG, Lopes DK, Reddy VK, du Mesnil de Rochemont R, Singer OC, Jahan R; SWIFT PRIME Investigators..

N Engl J Med. 2015 Jun 11;372(24):2285-95. doi: 10.1056/NEJMoa1415061. Epub 2015 Apr 17.


The quintessence of immunogenicity reporting for biotherapeutics.

Shankar G, Arkin S, Devanarayan V, Kromminga A, Quarmby V, Richards S, Subramanyam M, Swanson S.

Nat Biotechnol. 2015 Apr;33(4):334-6. doi: 10.1038/nbt.3181. No abstract available.


Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists..

AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24.


Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators..

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.


Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.

Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N; AIDS Clinical Trials Group Study 175 Protocol Team..

PLoS One. 2012;7(2):e31558. doi: 10.1371/journal.pone.0031558. Epub 2012 Feb 21.


Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Cortes JE, Kantarjian HM, Brümmendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C.

Blood. 2011 Oct 27;118(17):4567-76. doi: 10.1182/blood-2011-05-355594. Epub 2011 Aug 24. Erratum in: Blood. 2013 Oct 3;122(14):2524.


BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study.

Windyga J, Rusen L, Gruppo R, O'Brien AC, Kelly P, Roth DA, Arkin S.

Haemophilia. 2010 Sep 1;16(5):731-9. doi: 10.1111/j.1365-2516.2010.02239.x. Epub 2010 Mar 31.


Clinical outcomes in middle cerebral artery trunk occlusions versus secondary division occlusions after mechanical thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI trials.

Shi ZS, Loh Y, Walker G, Duckwiler GR; MERCI and Multi-MERCI Investigators..

Stroke. 2010 May;41(5):953-60. doi: 10.1161/STROKEAHA.109.571943. Epub 2010 Apr 8.


Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII.

Recht M, Nemes L, Matysiak M, Manco-Johnson M, Lusher J, Smith M, Mannucci P, Hay C, Abshire T, O'Brien A, Hayward B, Udata C, Roth DA, Arkin S.

Haemophilia. 2009 Jul;15(4):869-80. doi: 10.1111/j.1365-2516.2009.02027.x. Epub 2009 Apr 9.


Understanding the limits to generalizability of experimental evolutionary models.

Forde SE, Beardmore RE, Gudelj I, Arkin SS, Thompson JN, Hurst LD.

Nature. 2008 Sep 11;455(7210):220-3. doi: 10.1038/nature07152.


Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.

Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group..

J Thromb Haemost. 2008 Aug;6(8):1319-26. doi: 10.1111/j.1538-7836.2008.03032.x. Epub 2008 May 22.


Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial.

Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, Lutsep HL, Rymer MM, Higashida RT, Starkman S, Gobin YP; Multi MERCI Investigators., Frei D, Grobelny T, Hellinger F, Huddle D, Kidwell C, Koroshetz W, Marks M, Nesbit G, Silverman IE.

Stroke. 2008 Apr;39(4):1205-12. doi: 10.1161/STROKEAHA.107.497115. Epub 2008 Feb 28.


Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors.

Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, Ferran JM, Ljung RC; Novoseven (F7HAEM-1505) Investigators..

Haemophilia. 2008 May;14(3):466-75. doi: 10.1111/j.1365-2516.2008.01654.x. Epub 2008 Feb 12. Erratum in: Haemophilia. 2008 May;14(3):670.


Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis.

Yamamoto K, Nihrane A, Aglipay J, Sironi J, Arkin S, Lipton JM, Ouchi T, Liu JM.

Mol Med. 2008 Mar-Apr;14(3-4):167-74. doi: 10.2119/2007-00122.Yamamoto.


Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review.

Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY.

Haemophilia. 2007 Sep;13(5):508-17.


Constraints on microbial metabolism drive evolutionary diversification in homogeneous environments.

Gudelj I, Beardmore RE, Arkin SS, MacLean RC.

J Evol Biol. 2007 Sep;20(5):1882-9.


Language-enriched exercise plus socialization slows cognitive decline in Alzheimer's disease.

Arkin S.

Am J Alzheimers Dis Other Demen. 2007 Feb-Mar;22(1):62-77.


Supplemental Content

Loading ...
Support Center